Correction: Efficacy and safety of polymyxin B sulfate versus colistin sulfate in ICU patients with nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii: a multicenter, propensity score-matched, real-world cohort study

Correction: BMC Infect Dis 25, 390 (2025)

https://doi.org/10.1186/s12879-025-10773-1

Following publication of the original article [1], we were notified of a few corrections needed to Fig. 2 and Table 3:

Table 3.

The clinical outcomes and adverse events of ICU patients receiving PMB or CS for CRAB-caused nosocomial pneumonia

Characteristics	Before PSMa				After PSM
	Total (N = 232)	PMB (n = 132)	CS (n = 100)	P value	Total (N = 190)	PMB (n = 95)	CS (n = 95)	P value
Clinical responses
Success	162(69.8%)	89(67.4%)	73(73.0%)	0.360	139(73.2%)	69(72.6%)	70(73.7%)	0.871
Failure	70(30.2%)	43(32.6%)	27(27.0%)		51(26.8%)	26 (27.4%)	25(26.3%)
Microbiological responses
Eradication	45(19.4%)	24(18.2%)	21(21.0%)	0.771	40(21.1%)	20 (21.1%)	20 (21.1%)	1.000
Suppression	119(51.3%)	67(50.8%)	52(52.0%)		100(52.6%)	50(52.6%)	50 (52.6%)
Failure	68(29.3%)	41(31.0%)	27(27.0%)		50(26.3%)	25(26.3%)	25 (26.3%)
Mortality
14-days	40(17.2%)	25(18.9%)	15(15.0%)	0.431	30(15.8%)	16 (16.8%)	14 (14.7%)	0.691
28-days	71(30.6%)	47(35.6%)	24(24.0%)	0.057	54(28.4%)	31 (32.6%)	23(24.2%)	0.198
Adverse events
Overall AKIb	54(23.3%)	35(26.5%)	19(19.0%)	0.180	45(23.7%)	27(28.4%)	18(18.9%)	0.125
KDIGO 1	25(10.8%)	16(12.1%)	9(9.0%)	0.953	21(11.1%)	13(13.7%)	8(8.4%)	0.635
KDIGO 2	15(6.8%)	10(7.6%)	5(5.0%)		14(7.4%)	9(9.5%)	5(5.3%)
KDIGO 3	14(6.0%)	9(6.8%)	5(5.0%)		10(5.3%)	5(5.3%)	5(5.3%)
Hepatotoxicityc	36(15.5%)	24(18.2%)	12(12.0%)	0.198	24(12.6%)	13 (13.7%)	11(11.6%)	0.662
Mild	23(9.9%)	14(10.6%)	9(9.0%)	0.325	18(9.5%)	9(9.5%)	9(9.5%)	0.487
Moderate	8(3.5%)	6(4.6%)	2(2.0%)		6(3.2%)	4 (4.2%)	2 (2.1%)
Severe	5(2.2%)	4(3.0%)	1(1.0%)		0(0.0%)	0(0.0%)	0(0.0%)
Dermal toxicityd	21(9.1%)	21(15.9%)	0(0.0%)	< 0.001	18(9.5%)	18 (18.9%)	0 (0.0%)	< 0.001

1. a. PSM, propensity score matching

2. b. According to the KDIGO criteria, staging of acute kidney injury(AKI) as follows: (i) stage 1, serum creatinine 1.5 to 1.9 times baseline or ≥ 0.3 mg/dl (≥ 26.5 µmol/l) increase; (ii) stage 2, serum creatinine 2.0 to 2.9 times baseline; (iii) stage 3, serum creatinine serum creatinine 3.0 times baseline or ≥ 4.0 mg/dl (≥ 353.6 µmol/l) increase or initiation of renal replacement therapy

3. c. DILI severity classifications: i) mild: alanine transaminase (ALT) ≥ 5 or alkaline phosphatase (ALP) ≥ 2 and Total bilirubin (TBL) < 2 upper limit of normal (ULN); ii) Moderate: ALT ≥ 5 or ALP ≥ 2 and TBL ≥ 2 ULN, or symptomatic hepatitis; iii) Severe: ALT ≥ 5 or ALP ≥ 2 and TBL ≥ 2 ULN, or symptomatic hepatitis and 1 of the following criteria: international normalized ratio (INR) ≥ 1.5; ascites and/or encephalopathy, disease duration < 26 weeks, and absence of underlying cirrhosis; Other organ failure due to DILI; iiii) Fetal/transplantation: death or liver transplantation due to DILI

4. d. 5 cases of skin rashes and 13 with skin pigmentation in the PMB cohort

5. Definition of skin hyperpigmentation: A disorder characterized by darkening of the skin due to excessive melanin deposition

-the labels "a" and "b" in Fig. 2 had been reversed;

-there was a discrepancy between the hepatotoxicity data presented in Table 3 and the descriptions in the main text

Originally published Table 3:

Corrected Table 3:

Table 3.

The clinical outcomes and adverse events of patients receiving PMB or CS for CRAB nosocomial pneumonia

Characteristics	Before PSMa				After PSM
	Total (N = 232)	PMB (n = 132)	CS (n = 100)	P value	Total (N = 190)	PMB (n = 95)	CS (n = 95)	P value
Clinical responses
Success	162(69.8%)	89(67.4%)	73(73.0%)	0.360	139(73.2%)	69(72.6%)	70(73.7%)	0.871
Failure	70(30.2%)	43(32.6%)	27(27.0%)		51(26.8%)	26 (27.4%)	25(26.3%)
Microbiological responses
Eradication	45(19.4%)	24(18.2%)	21(21.0%)	0.771	40(21.1%)	20 (21.1%)	20 (21.1%)	1.000
Suppression	119(51.3%)	67(50.8%)	52(52.0%)		100(52.6%)	50(52.6%)	50 (52.6%)
Failure	68(29.3%)	41(31.0%)	27(27.0%)		50(26.3%)	25(26.3%)	25 (26.3%)
Mortality
14-days	40(17.2%)	25(18.9%)	15(15.0%)	0.431	30(15.8%)	16 (16.8%)	14 (14.7%)	0.691
28-days	71(30.6%)	47(35.6%)	24(24.0%)	0.057	54(28.4%)	31 (32.6%)	23(24.2%)	0.198
Adverse events
Overall AKIb	54(23.3%)	35(26.5%)	19(19.0%)	0.180	45(23.7%)	27(28.4%)	18(18.9%)	0.125
KDIGO 1	25(10.8%)	16(12.1%)	9(9.0%)	0.953	21(11.1%)	13(13.7%)	8(8.4%)	0.635
KDIGO 2	15(6.8%)	10(7.6%)	5(5.0%)		14(7.4%)	9(9.5%)	5(5.3%)
KDIGO 3	14(6.0%)	9(6.8%)	5(5.0%)		10(5.3%)	5(5.3%)	5(5.3%)
Hepatotoxicityc	12(5.2%)	8(6.0%)	4(4.0%)	0.483	10(5.3%)	6 (6.4%)	4(4.3%)	0.516
Mild	7(3.0%)	4(3.0%)	3(3.0%)	0.428	6(3.2%)	3(3.2%)	3(3.2%)	0.453
Moderate	5(2.2%)	4(3.0%)	1(1.0%)		4(2.1%)	3 (3.2%)	1 (1.1%)
Dermal toxicityd	21(9.1%)	21(15.9%)	0(0.0%)	< 0.001	18(9.5%)	18 (18.9%)	0 (0.0%)	< 0.001

a. PSM, propensity score matching

b. According to the KDIGO criteria, staging of acute kidney injury(AKI) as follows: i) stage 1, serum creatinine 1.5 to 1.9 times baseline or ≥ 0.3 mg/dl (≥ 26.5 μmol/l) increase; ii) stage 2, serum creatinine 2.0 to 2.9 times baseline; iii) stage 3, serum creatinine serum creatinine 3.0 times baseline or ≥ 4.0 mg/dl (≥ 353.6 μmol/l) increase or initiation of renal replacement therapy

c. DILI severity classifications: i)mild: alanine transaminase (ALT) ≥ 5 or alkaline phosphatase (ALP) ≥ 2 and Total bilirubin (TBL) < 2 upper limit of normal (ULN); ii)Moderate: ALT ≥ 5 or ALP ≥ 2 and TBL ≥ 2 ULN, or symptomatic hepatitis; iii) Severe: ALT ≥ 5 or ALP ≥ 2 and TBL ≥ 2 ULN, or symptomatic hepatitis and 1 of the following criteria: international normalized ratio (INR) ≥ 1.5; ascites and/or encephalopathy, disease duration < 26 weeks, and absence of underlying cirrhosis; Other organ failure due to DILI; iiii) Fetal/transplantation: death or liver transplantation due to DILI

d. 5 case of skin rashes and 13 with skin pigmentation in the PMB group

The original article has been corrected.